XTalks

AUGUST 18, 2021

While infectious disease experts and drug companies have rightfully spent the last 18 months developing therapeutics and vaccines targeting SARS-CoV-2 and COVID-19, another global threat to public health — antimicrobial resistance (AMR) — has, and will continue to, persist until similar direct action is taken.

Development 105

Development Bacteria Drugs Vaccination 105

The Pharma Data

DECEMBER 31, 2020

“Antibody responses are not likely to be the sole determinant of someone’s outcome,” said Scott Boyd, associate professor of pathology at Stanford. Some of these patients mount a vigorous immune response, and others have a more moderate response. There are also other branches of the immune system involved.

Antibody 52

Antibody Research Bacteria Genetics 52

The Pharma Data

DECEMBER 13, 2020

SYNB1891 is an investigational drug for the intra-tumoral treatment of solid tumors and lymphoma, composed of an engineered Synthetic Biotic designed to activate the STING pathway in the tumor microenvironment in order to upregulate the patient’s immune response. CAMBRIDGE, Mass. , Sokolovska, A.,

Immune Response 40

Immune Response Engineer Medicine Clinical Trials 40

The Pharma Data

OCTOBER 19, 2020

Immune responses following vaccination with PNEUMOVAX 23 (month 13) were comparable in both vaccination groups for the 15 serotypes in V114. Results from both studies are based on opsonophagocytic activity (OPA) responses – a measure of vaccine-induced functional antibodies. among adults 65 years of age or older.

Vaccination 52

Vaccination Vaccine Immune Response Containment 52

Pfizer

FEBRUARY 16, 2023

Food and Drug Administration (FDA) and Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) in 2025, pending successful completion of the Phase 3 studies and subject to the agreement of these regulatory agencies to proposed modifications of the clinical trial plan. FDA in July 2017.

Clinical Trials 76

Clinical Trials Clinical Trials Vaccination Vaccine 76

XTalks

NOVEMBER 28, 2022

It may be caused by the immune system being triggered by a virus or bacteria that results in an atypical immune response, or genetics play a role in disease development as it is more common in people whose immediate family members have Crohn’s disease.

Trials 52

Trials Immune Response Bacteria Development 52

The Pharma Data

DECEMBER 15, 2020

Many drug makers are investing in new science and hope to develop new therapeutics that address autoimmune disease. Scientists will be testing a drug class targeting the C-reactive protein (CRP) marker of acute inflammation in the body. They’ll use software that searches available drugs, as well as drug-like compounds.

Clinical Trials 52

Clinical Trials Clinical Trials Antibody Trials 52

The Pharma Data

JUNE 18, 2021

Food and Drug Administration (FDA) has approved PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) for the prevention of invasive disease and pneumonia caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes in the vaccine in adults ages 18 years and older. “We NEW YORK–(BUSINESS WIRE)– Pfizer Inc.

Vaccination 52

Vaccination Vaccine FDA Approval Containment 52

XTalks

DECEMBER 17, 2021

Developing a highly effective vaccine against malaria has been technically challenging because malaria has a large and complex genome, and it’s why it’s generally more difficult to develop a vaccine against parasites than smaller viruses and bacteria.

Life Science 98

Life Science Vaccination Vaccine Trials 98

Pharmaceutical Technology

MARCH 24, 2023

TB is caused by the bacillus Mycobacterium tuberculosis and is transmitted when infected individuals expel bacteria into the air (e.g., In light of World TB day on March 24, the field hopes to overcome some major barriers to the drug development landscape. by coughing). million new cases reported worldwide.

Vaccination 162

Vaccination Vaccine Clinical Trials Trials 162

XTalks

MARCH 24, 2025

Fabhalta works by inhibiting factor B, a key enzyme in the alternative complement pathway, thus calming the damaging immune response. Due to a risk of serious infections from encapsulated bacteria, its use is limited to a Risk Evaluation and Mitigation Strategy requiring specific vaccinations.

Bioavailability 71

Bioavailability Immune Response Protein Bacteria 71